Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Inhibition of Myopia Progression With Optical Devices

7. Juli 2026 aktualisiert von: Barcsay-Veres Amarilla, Semmelweis University

This observational study aims to determine whether optical devices designed to slow myopia progression and/or environmental factors can prevent myopia progression in the pediatric and adolescent myopic population.

The study aims to answer the following questions:

  1. How does myopia progression change with age while wearing myopia progression control glasses?
  2. How does myopia progression change while wearing myopia progression-control glasses when environmental factors, such as time spent outdoors and place of residence, are taken into account?
  3. How does myopia progression change at different ages while wearing myopia progression control glasses given a family history of myopia? This will be a self-controlled observational study. Participants who are myopic after cycloplegic refraction will be prescribed DIMS glasses. DIMS stands for "defocus incorporated multiple segments," a specialized optical technology used in spectacle lenses to slow nearsightedness progression in children.

Patients will keep a diary of their subjective symptoms and environmental factors, e.g., time spent outdoors and screen time.

Patients will visit the clinic once every six months for checkups and the following tests:

  • Best corrected visual acuity test
  • Stereopsis
  • Automatic refractometry
  • Bulbar axial length measurement

In a follow-up study, researchers will compare myopia progression with environmental and baseline factors to learn about the long-term effects of DIMS lenses on myopia progression.

Studienübersicht

Detaillierte Beschreibung

As an observational study we aim to examine the effects of D.I.M.S. lens's daily wear on myopia progression in relation to the environmental factors.

Our pediatric and adolescent myopic population is selected as follows:

Inclusion Criteria:

  • Participants must be between 6 and 15 years of age at the start of myopia progression treatment
  • Caucasian ethnicity
  • Refractive error measured under cycloplegia, expressed as spherical equivalent: between -0.50 Dsph and -10.0 Dsph
  • Wearing myopia-control glasses during waking hours
  • Willing to Participate in follow-up examinations up to 24 weeks

Exclusion criteria:

  • pathological myopia (e.g., myopia onset before age 6, Stickler syndrome)
  • preterm infants born before 32 weeks of gestation
  • previous eye-opening surgery (e.g., lens extraction)
  • Traumatic eye injury
  • Known connective tissue disorder (e.g., Marfan syndrome)
  • Irregular or improper use of progressive-lens glasses
  • Failure to attend the follow-up examinations scheduled

In the self-controlled observational study the myopic participants are wearing during day time DIMS glasses. DIMS stands for "defocus incorporated multiple segments," a specialized optical technology used in spectacle lenses to slow nearsightedness progression in children. DIMS glasses not only correct the refractive errror but also provide a circular defocus zone to avoid periferial retinal defocus.

Patients will keep a diary of their subjective symptoms and environmental factors, e.g., time spent outdoors and screen time, subjective symptoms.

Patients will visit the clinic once every six months for checkups and the following tests:

  • Best corrected visual acuity test
  • Stereopsis
  • Automatic refractometry
  • Bulbar axial length measurement These measurements and tests are part of the regular ophthalmological follow-up examinations.

The study aims to answer the following questions:

  1. How does myopia progression change with age while wearing myopia progression control glasses?
  2. How does myopia progression change while wearing myopia progression-control glasses when environmental factors, such as time spent outdoors and place of residence, are taken into account?
  3. How does myopia progression change at different ages while wearing myopia progression control glasses given a family history of myopia? Statistical analysis plan includes non-parametric t-test, one way and two way ANOVA tests.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

50

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Budapest, Ungarn, 1085
        • Rekrutierung
        • Semmelweis University Ophthalmology Department
        • Kontakt:
        • Kontakt:
        • Unterermittler:
          • Otto A Maneschg, PhD
        • Unterermittler:
          • Amarilla Barcsay-Veres, PhD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind

Akzeptiert gesunde Freiwillige

Nein

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

Participants (between 6 and 15 years of age) are wearing myopia progression treatment , namely D.I.M.S. lenses while they are awake. The wear these glasses to correct refractive error and to slow down myopia progression.

At enrollment the refractive error measured under cycloplegia, expressed as spherical equivalent must be: between -0.50 Dsph and -10.0 Dsph.

Beschreibung

Inclusion Criteria:

  • • Participants must be between 6 and 15 years of age at the start of myopia progression treatment

    • Caucasian ethnicity
    • Refractive error measured under cycloplegia, expressed as spherical equivalent: between -0.50 Dsph and -10.0 Dsph
    • Wearing myopia-control glasses while awake
    • Participation in follow-up examinations every 6 months

Exclusion Criteria:

  • • Pathological myopia (e.g., myopia onset before age 6, Stickler syndrome)

    • Premature birth before the 32nd week of gestation
    • Previous eye-opening surgery (e.g., lens removal)
    • Traumatic eye injury
    • Known connective tissue disorder (e.g., Marfan syndrome)
    • Irregular or improper use of progressive-lens glasses
    • Failure to attend the follow-up examinations scheduled every 6 months

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Myopic cohort

Inclusion Criteria:

  • Participants must be between 6 and 15 years of age at the start of myopia progression treatment
  • Caucasian ethnicity
  • Refractive error measured under cycloplegia, expressed as spherical equivalent: between -0.50 Dsph and -10.0 Dsph
  • Wearing myopia-control glasses while awake
  • Participation in follow-up examinations every 6 months

Exclusion criteria:

  • Pathological myopia (e.g., myopia onset before age 6, Stickler syndrome)
  • Premature birth before the 32nd week of gestation
  • Previous eye-opening surgery (e.g., lens removal)
  • Traumatic eye injury
  • Known connective tissue disorder (e.g., Marfan syndrome)
  • Irregular or improper use of progressive-lens glasses
  • Failure to attend the follow-up examinations scheduled every 6 months
DIMS (Defocus Incorporated Multiple Segments) lenses wearing while awake
D.I.M.S. lenses are worn like normal glasses to correct myopia and, beyond that, their special design is intended to slow myopia progression via defocus lenslets. There is targeted myopic defocus produced by the mid-peripheral lenslets with positive power to inhibit eye length growth.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Best corrected visual acuity test
Zeitfenster: up to 24 week
Zero is equivalent to no vision and 1.0 indicates the best visual acuity in decimal scale. Distance and near visual acuity is measured under standard conditions
up to 24 week
Bulbar axial length measurement
Zeitfenster: up to 24 week
It is defined as the distance from the anterior surface of the cornea to the retinal pigment epithelium, measured in millimeters using optical device. An increase in axial length is characteristic of the elongation of the eye.
up to 24 week

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Stereopsis
Zeitfenster: up to 24 week
stereopsis test (depth perception test) measures how well the eyes create three-dimensional vision. The precision of depth perception is measured in seconds of arc (arcsec) using a test plate. If stereoscopic vision is present, the smaller the angle, the more refined the stereopsis.
up to 24 week

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Zoltan Zs Nagy, Professor, Semmelweis University Ophthalmology Department

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

2. Juni 2026

Primärer Abschluss (Geschätzt)

31. Mai 2027

Studienabschluss (Geschätzt)

31. Mai 2027

Studienanmeldedaten

Zuerst eingereicht

27. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

7. Juli 2026

Zuerst gepostet (Tatsächlich)

13. Juli 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. Juli 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

7. Juli 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

3
Abonnieren